Abstract
Patent ductus arteriosus(PDA)is a common condition that primarily occurs in preterm infants who with low birth weight, which closely related to several co-morbidities(intracranial hemorrhage, necrotizing enterocolitis, pulmonary edema/hemorrhage, bron chopulmonary dysplasia, and retinopathy). Although the color Doppler ultrasound assessment can be used as the gold standard to determine the present of PDA, it is still very hard to fully reflect the hemodynamic change occured in PDA case.In recent years, B-type natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP), two kind of biological markers, were used in the premature infants to assess the present, shunt volume, progress and durg or surgical intervention indication of PDA.In this paper, the corrections of PDA between BNP and NT-proBNP were reviewed briefly. Key words: Patent ductus arteriosus; B-type natriuretic peptide; N-terminal pro-brain natriuretic peptide; Preterm infant
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
